Large gap with delayed quotes
|
Last quote
10/16/2026
-
15:47:05
|
Bid
10/16/2026 -
15:48:55
|
Bid Volume |
Ask
10/16/2026 -
15:48:55
|
Ask Volume |
|---|---|---|---|---|
|
33.61
-0.72
(
-2.10% )
|
33.52
|
100 |
33.68
|
100 |
Analysis date: 13.10.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 09.10.2026.
Quality
Weak
Weak
Two stars since 09.10.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 09.10.2026 at a price of 36.44.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The stock appears oversold from a technical perspective due to its recent losses. It trades below its forty day technical trend since 28.08.2026.
4wk Rel Perf
-43.25%
-43.25%
The stock appears oversold from a technical perspective, with a four week dividend-adjusted underperformance of of 43.25% behind the SP500.
Risk
Middle
Middle
The stock has been on the moderate-sensitivity level since 09.10.2026.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.84%.
Mkt Cap in $bn
3.47
3.47
With a market capitalization between $2 & $8bn, XENON PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
0.22
0.22
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
205.25
205.25
The estimated PE is for the year 2029.
LT Growth
45.35%
45.35%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
14
14
Over the last seven weeks, an average of 14 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
60
60
For 1% of index variation, the stock varies on average by 0.60%.
Correlation
0.12
0.12
Stock movements are totally independent of index variations.
Value at Risk
4.13
4.13
The value at risk is estimated at USD 4.13. The risk is therefore 12.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
15.07.2025
15.07.2025